Unlike exenatide, which is derived from exendin-4, semaglutide is a synthetic analog of human GLP-1, engineered for a significantly longer half-life and greater potency.[119] Although both drugs fall under the same therapeutic class, their differing pharmacological profiles illustrate how follow-on biopharmaceutical innovation can enhance clinical efficacy, usability, and patient reach over time
I think- Andrew Huberman: Okay, great
Peptidases, such as DPP4, are known to regulate functional activity of chemokines
Important safety considerations : Never increase doses beyond prescribed amounts without medical supervision, don't combine weight loss medications without physician approval, and report concerning symptoms immediately
Obesity prevalence in the Gulf region exceeds 30%, while diabetes rates in some countries surpass 20%, driving increased adoption of GLP-1 therapies